Icon

CREXONT (NDA217186)- (35MG;140MG,52.5MG;210MG,70MG;280MG,87.5MG;350MG)

CARBIDOPA; LEVODOPA IMPAX
35MG;140MG,52.5MG;210MG,70MG;280MG,87.5MG;350MG
Yes Yes
2041-Dec-21 Expired
None 2027-Aug-07
None No
CREXONT is a combination of carbidopa (an aromatic amino acid decarboxylation inhibitor) and levodopa (an aromatic amino acid) indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.
0 0 0
Total Other Developers None
Drugs with Suitability No
35MG;140MG ** ** - - -
52.5MG;210MG ** ** - - -
70MG;280MG ** ** - - -
87.5MG;350MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.